• Vijayakumar A. E. Asistant profesor , ESIC Medical college& PGIMSR
  • Vinay M. ESIC Medical College and PGIMSR
  • Seethalakshmi . ESIC Medical College and PGIMSR


Objective: Side effects and development of tolerance to antiepileptic drugs necessitate identifying alterative and improved approaches to treat epilepsy. Bacopa monniera (BM), is a natural product which is used to treat epilepsy. We evaluated effect of co-administration of BM with phenobarbitone (PHB) to prevent development of tolerance to PHB.

Methods: Male Swiss albino mice (25-30 gm-) were divided into six groups. Group 1 and 2 served as controls, which received vehicle and PHB (25 mg/kg, i. p.) respectively. In Group 3 maximal electric shock (MES) was induced two hs following administration of PHB (25 mg/kg, i. p.) at alternate day for 18 d. Hind limb tonic extension (HLTE) occurrence on two consecutive days was set as end point. In Group 4, 5 and 6 MES was induced 2 h following co-administration of PHB (25 mg/kg, i. p.) and BM (250, 500 or 750 mg/kg p. o. respectively). Mice behavior tests were performed at the end of the18thday, following which mice were sacrificed and brain was isolated for estimation of malonoldehyde (MDA) and reduced glutathione (GSH) levels.

Results: 82.5% of mice from group 3 developed tolerance to antiepileptic effects of PHB. Co-administration of BM (250, 500 and 750 mg/kg) lead to development of PHB tolerance in 82.5%, 25% and 20% respectively. This beneficial effect of BM was associated with reduced MDA levels and increased GSH levels in brain, suggesting a role of antioxidant pathways in preventing development of tolerance to antiepileptic effects of PHB.

Conclusion: Co-administration of BM prevented the development of tolerance to antiepileptic effects of PHB.


Keywords: Bacopa monniera, Phenobarbitone, Tolerance, Behavioral parameters, Oxidative stress


Download data is not yet available.


1. Available from: URL: mediacentre/factsheets/fs999/en/index.html. [Last accessed on 06 Nov 2010].
2. Available from: URL: linkfiles/information and documents facts. pdf [Last accessed on 06 Nov 2010].
3. Berg AT. Identification of pharmacoresistant epilepsy. Neurol Clin 2009;27:1003-13.
4. Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia 2012;53:40-6.
5. Bacopa monniera. Monograph. Altern Med Rev 2004;9:79-85.
6. Tripathi YB, Chaurasia S, Tripathi E, Upadhyay A, Dubey GP. Bacopamonniera Linn as an antioxidant: mechanism of action. Indian J Exp Biol 1996;34:523-6.
7. Ganguly DK, Malhtora CL. Some neuropharmacological and behavioural effects of an active fraction from Herpestismonniera, Linn (Brahmi). Indian J Physiol Pharmacol 1967;11:33-43.
8. Krishnakumar A, Nandhu MS, Paulose CS. Upregulation of 5-HT2C receptors in hippocampus of pilocarpine-induced epileptic rats: antagonism by Bacopamonnieri. Epilepsy Behav 2009;16:225-30.
9. Goodman LS, Grewal MS, Brown WC, Swinyard EA. Comparison of maximal seizures evoked by pentylenetetrazol (metrazol) and electroshock in mice, and their modification by anticonvulsants. J Pharmacol Exp Ther 1953;108:168-76.
10. Schmidt D, Kupferberg HJ, Yonekawa W, Penry JK. The development of tolerance to the anticonvulsant effect of phenobarbital in mice. Epilepsia 1980;21:141-7.
11. Reeta KH, Mehla J, Gupta YK. Curcumin is protective against phenytoin-induced cognitive impairment and oxidative stress in rats. Brain Res 2009;1301:52-60.
12. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
13. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7.
14. Luoni C, Bisulli F, Canevini MP. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 2011;52:2181-91.
15. Schiller Y. Seizure relapse and development of drug resistance following long term seizure remission. Arch Neurol 2009;66:1233–9.
16. Beleza P. Refractory epilepsy: a clinically oriented review. Eur Neurol 2009;62:65-71.
17. Tishler DM, Weinberg KT, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
18. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003;16:197–201.
19. Loscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006;47:1253-83.
20. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopamonnieri in Alzheimer's disease model. J Ethnopharmacol 2010;127:26-31.
21. Wahab A, Albus K, Gabriel S, Heinemann U. In search of models of pharmacoresistant epilepsy. Epilepsia 2010;51(Suppl 3):154–9.
22. Lopez J, Gonzalez ME, Lorigados L, Morales L, Riverón G, Bauza JY. Oxidative stress markers in surgically treated patients with refractory epilepsy. Clin Biochem 2007;40:292-8.
23. Mathew J, Soman S, Sadanandan J, Paulose CS. Decreased GABA receptor in the striatum and spatial recognition memory deficit in epileptic rats: effect of Bacopa monnieri and bacoside-A. J Ethnopharmacol 2010;130:255-61.
24. Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003;4:S25–38.
25. Gastens AM, Brandt C, Bankstahl JP, Löscher W. Predictors of pharmacoresistant epilepsy: pharmacoresistant rats differ from pharmacoresponsive rats in behavioral and cognitive abnormalities associated with experimentally induced epilepsy. Epilepsia 2008;49:1759-76.
188 Views | 465 Downloads
How to Cite
E., V. A., V. M., and S. . “METHANOLIC EXTRACT OF BACOPA MONNIERA REDUCE DEVELOPMENT OF TOLERANCE TO ANTIEPILEPTIC EFFECT OF PHENOBARBITONE IN MICE”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 11, Aug. 2015, pp. 256-9,
Original Article(s)